proactiveinvestors.com
Mesoblast reports $US35.1m in gross revenue from sales of its cell therapy Ryoncil
Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) reported $US35.1 million ($52.4 million) in gross revenue from Ryoncil sales in the December quarter, up 60% on the...